menu
    • menu
    [{"orgOrder":0,"company":"Peptris Technologies","sponsor":"Revio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Undisclosed","year":"2025","type":"Licensing Agreement","leadProduct":"RT001","moa":"Lipid peroxidation","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Peptris Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peptris Technologies \/ Revio Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Peptris Technologies \/ Revio Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals for RT001

    Menu

    RT001

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Peptris Technologies

    India arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed

    Peptris Technologies

    India arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : RT001

    Therapeutic Area : Genetic Disease

    Study Phase : Preclinical

    Sponsor : Revio Therapeutics

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Peptris Technologies out-licenses AI-discovered drug candidate to Revio Therapeutics

    Details : Under the licensing agreement, Revio will hold commercialisation rights to PEPR124 (RT001) in all markets except in BRICS countries, which will be retained by Peptris.

    Product Name : PEPR124

    Product Type : Undisclosed

    Upfront Cash : Undisclosed

    March 17, 2025

    Lead Product(s) : RT001

    Therapeutic Area : Genetic Disease

    Highest Development Status : Preclinical

    Sponsor : Revio Therapeutics

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth